CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 474 enrolled
Drug / intervention
Antivenom serum Inoserp Pan-Africa® injectiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03326492
NCT03326492N/ACompleted
CompareCT.gov

Evaluation of Anti-venoms Serum in Africa (ESAA). Data Collection in Real Life Conditions

Institut Pasteur·observational·Posted Oct 31, 2017·Updated Sep 22, 2025

In Brief

An observational study evaluating Antivenom serum Inoserp Pan-Africa® injection for Snake Bites and 2 related conditions. Completed, enrolled 474 participants across 13 sites.

Detailed Summary

There is little or no assessment under real-use conditions of the efficacy and the tolerance in the short, medium and long term of the antivenoms currently on the market and used in the treatment of snake bites. The main objective is to assess the short term tolerance (\< 2 hours post-injection) of the antivenom Inoserp Pan-Africa® (temporary market authorization) from Inosan laboratory currently available in Cameroon.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsSnake Bites, Antivenins, Snake Venoms
CountriesCameroon
CollaboratorsCameroon Society of Epidemiology (CaSE), Centre International de Recherches d'Enseignements et de Soins (CIRES), Centre Pasteur du Cameroun, Inosan Biopharma

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedOct 31, 2017
Enrollment StartOct 17, 2019
Primary CompletionSep 14, 2021
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 8.7 years ago

Interventions

Antivenom serum Inoserp Pan-Africa® injectiondrug

Participation to the study does not change usual follow-up of patients. All medical procedures will be performed and products will be used in a routine manner. Antivenom serum Inoserp Pan-Africa® injection will be decided according to the clinical evaluation of the patient.